Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2019 to Jul 2024
Activity Initiated by Company and Dr. Nusbacher Filing Provisional
Patent for Treatment of Avian Flu Utilizing IVIg Therapy
Gammacan International (OTC BB:GCAN), a developer of
immunotherapies for cancer and other diseases, today announced that
Dr. Jacob Nusbacher has accepted an appointment as Medical Advisor to
the Company to oversee the Phase II Clinical trial of GCAN 101 for the
treatment of metastatic cancer and to expand the Company's pipeline in
plasma-based products.
The Company concurrently announced that in line with Dr.
Nusbacher's mission of expanding Gammacan's platform of IVIg-based
products it filed a Provisional Patent with the U.S. patent office for
the utilization of IVIg therapy as a potential treatment for avian flu
using IVIg from previously infected patients and from those previously
immunized. IVIg has been efficacious in treating other viral diseases
such as Hepatitis B, and Rabies.
"Dr. Nusbacher's research and experience in hematology,
immunology, and plasma coupled with his expertise in initiating and
managing clinical trials is truly extraordinary and will be of great
assistance to Gammacan as we continue our Phase II trial of GCAN 101
for the treatment of metastatic cancer," stated Vered Caplan, CEO.
A major east coast publication, reported yesterday in an article
focused on avian flu, "We know that viruses mutate and strike in
unpredictable ways. It is plausible that this virus might mutate as
has been predicted and that an epidemic - or even a pandemic - might
result. Since we cannot predict exactly how, where, or when the virus
might mutate, we need a response that is both preventative and
adaptive."
Vered Caplan, CEO, commented, "We believe that Dr. Nusbacher's
expertise will be of great assistance in furthering the Company's
product pipeline. Because of the serious public health hazard that
avian flu could present, Gammacan is presently exploring the
possibilities that IVIg may hold in this area."
About Dr. Nusbacher
Dr. Nusbacher is a leading expert in the field of
immunohematology, and has extensive experience in both the scientific
and business aspects of human plasma- derived therapies. Prior to
joining GammaCan, he served as Medical Director of Kamada Ltd, a
pharmaceutical company specializing in drugs manufactured from human
plasma. He has also served as National Director of the Canadian Red
Cross Blood Transfusion Service and has directed major regional blood
centers in the United States and Canada. In addition, Dr. Nusbacher
has held the position of Professor of Medicine at the Universities of
Rochester, Pittsburgh and Toronto, and was Visiting Professor at Tel
Aviv University. He has more than 100 scientific publications to his
credit.
Dr. Nusbacher has also served as a member of the first FDA Panel
on Blood and Blood Products (BPAC) for five years and on the Editorial
Board of the Journal Transfusion for 20 years. Dr. Nusbacher has and
has designed and led clinical trials for a number of different drugs
as part of the process in obtaining FDA approval. He has consulted for
major U.S. companies including DuPont, Bayer, and Alpha Therapeutics.
About GammaCan:
GammaCan is focusing on the commercialization of a revolutionary
anti-cancer immunotherapy that the Company believes will be proven to
be effective in reducing the metastatic spread of a wide range of
cancers. GammaCan's proposed treatment is based on IVIG, a safe,
relatively non-toxic human plasma-based product, currently used to
treat a variety of immune deficiencies and autoimmune diseases. It
works by strengthening the patient's immune system. Many experts
currently view immunotherapy as a future alternative to today's
standard chemotherapy. Approximately twenty companies produce IVIG,
and annual worldwide sales are currently in excess of 50 metric tones
with an estimated value in excess of 1.5 billion USD. IVIG is commonly
used to treat certain autoimmune diseases and blood disorders and to
replace the antibodies in people who are unable to produce them. For
more information about GammaCan visit www.gammacan.com or call the
company's headquarters in Givat Shmuel, Israel at 972 3 5774475.
Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding: the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IVIG into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, inability to hire appropriate staff to develop the
technology, unforeseen technical difficulties in developing the
technology, inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early stage medical
research and development companies filed with the SEC on Edgar.